Tag: the war on (some) drugs

Ohio CBD Retailers Push Back Against Effort To Limit Hemp Products To Marijuana Dispensaries

Ohio CBD store owners are concerned about a bill that would regulate intoxicating hemp and drinkable cannabinoid products something that could potentially put them out of business.

Fourteen people submitted opponent testimony and four people submitted supporter testimony for Ohio Senate Bill 86 during Tuesday’s Senate General Government Committee meeting. No supporters showed up at the meeting to testify in person.

“Should these restrictions pass, they would eliminate 90 percent of the non-intoxicating full-spectrum hemp products we currently offer,” said Jaimee Courtney, owner of Bellefontaine’s Sunmed Your CBD Store. “This would drive consumers to unregulated online markets, creating potential safety risks and diverting significant tax revenue out of Ohio.”

The bill would require intoxicating hemp products to be sold only at adult-use marijuana dispensaries instead of allowing them to be sold at CBD stores, convenience stores, smoke shops or gas stations.

The bill would also impose a 15 percent tax on intoxicating hemp products, ban sales to anyone under 21 and only allow intoxicating hemp products to be sold at dispensaries if the products have been tested and comply with standards for packaging, labeling and advertising.

Ohio state Sens. Steve Huffman (R-Tipp City) and Shane Wilkin (R-Hillsboro) introduced SB 86. Eleven people submitted testimony in support of the bill last week—including people in the marijuana business, poison control workers and religious organizations.

“The people walking into our stores are not looking to get high, they are looking for relief,” said Robert McClure, owner of Centerville and Deerfield Township’s Sunmed Your CBD Store. “Most of our customers will not go to a dispensary for a multitude of reasons.”

He said his store requires customers to be at least 21 years old to buy their products, which are all third-party tested.

“We have concerns that the language in SB 86 would ban most of all other types of hemp products from retail sales and driving them to an unsafe, illicit environment with no age restrictions,” said Kristin Mullins, president of the Ohio Grocers Association.

Keep reading

Nevada Lawmakers Discuss Plan To Create Psychedelic Therapy Pilot Program

A Nevada bill that would create a psychedelic therapy pilot program for military veterans and first responders had its first committee hearing on Wednesday. Lawmakers heard testimony from reform advocates, veterans and their families and members of a state Psychedelic Medicines Working Group, which late last year called on lawmakers to establish a system for regulated access.

The legislation, AB 378, was filed March 10 by Assemblymember Max Carter (D) and 18 other cosponsors. Under the proposal, the state would establish an Alternative Therapy Pilot Program under the Department of Health and Human Services (HHS).

The program would allow the medically supervised use of psychedelics including psilocybin, DMT, ibogaine and mescaline, specifically among military veterans and first responders with certain mental health conditions.

While the Assembly Committee on Health and Human Services didn’t act on the legislation at Wednesday’s hearing, they took testimony and asked questions of some speakers.

Carter, speaking to the panel, said that psychedelic therapy—involving ketamine, which is not part of the current bill—helped him overcome “profound, deep grief, treatment-resistant depression” and complex post-traumatic stress disorder after the traumatic death of his wife.

He explained that the pilot program would focus on first responders and military veterans because “those are demographics that everybody can identify with, but more importantly, they’re ones with accelerated—or exacerbated—suicide rates.”

“When we come back here in two years,” Carter told colleagues, “my belief is this will be mainstream therapy.”

Notably, no members of the public at Wednesday’s hearing spoke in opposition to the proposal, nor did any offer neutral comments.

Keep reading

Florida House And Senate Panels Pass Bills To Criminalize Sales Of Psychedelic Mushroom Spores

Agricultural legislation in Florida containing a provision to outlaw psychedelic mushroom spores has proceeded past two more lawmaking panels in the House and Senate.

The proposed ban on spores of mushrooms that create psilocybin or psilocin is part of roughly 150-page companion bills that would make a variety of adjustments to Florida’s agricultural laws, including around agricultural lands, utilities and wildlife management.

With respect to psychedelic mushrooms, both would outlaw transporting, importing, selling or giving away “spores or mycelium capable of producing mushrooms or other material which will contain a controlled substance, including psilocybin or psilocyn, during its lifecycle.”

Violating the proposed law would be a first-degree misdemeanor, carrying a maximum one year in jail and $1,000 fine.

On Wednesday, the House Criminal Justice Subcommittee passed HB 651, from sponsor Rep. Kaylee Tuck (R), on a 14–4 vote. Prior to the vote, the body adopted an amendment that simplifies the language of the psychedelic spore prohibition but doesn’t meaningfully change it.

Tuck explained to members at the hearing that the change “restructures” the language “to simplify the prohibition without changing the substance of the underlying bill.”

Later in the day, the Senate Appropriations Committee on Agriculture, Environment and General Government favorably reported SB 700, by Sen. Keith Truenow (R).

While senators didn’t discuss the bill’s spore provision at the hearing, one public commenter, identified as Daniel Freeman, opposed it.

Keep reading

Trump’s First Pick For Attorney General Says Marijuana Rescheduling Is ‘On The Horizon’

Former Rep. Matt Gaetz (R-FL)—President Donald Trump’s first pick for U.S. attorney general this term before he withdrew from consideration—says “meaningful” marijuana reform is “on the horizon” under the current administration, praising the president’s “leadership” in supporting rescheduling.

In an op-ed published by The Tampa Bay Times on Thursday, Gaetz said that moving cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA) “won’t solve every problem overnight, but it is a necessary step in the right direction.” And he expressed confidence that Trump will bring about that reform.

The former lawmaker’s column omits mention of the fact that former President Joe Biden initiated the rescheduling review that led federal agencies to recommend the reclassification. And while it’s true that, during his 2024 campaign, Trump endorsed the policy change in a social media post, he has not publicly discussed marijuana issues since taking office.

In any case, Gaetz said today “there is meaningful change finally on the horizon, thanks to President Donald Trump and his leadership in supporting the rescheduling of cannabis from a Schedule I drug to a Schedule III drug.”

Gaetz said he’s “always believed that marijuana laws should be rooted in science, not stigma,” citing his work to advance reform during his time in the Florida House and Congress.

However, he seemed to mischaracterize his contribution to the issue in the state legislature, claiming he introduced legislation at the time to “legalize marijuana because I understood that our outdated federal policies were failing patients, veterans and businesses.” Gaetz did sponsor a limited medical cannabis bill, but not a full-out legalization measure. In Congress, he was one of the sole GOP votes to support a Democrat-led federal legalization bill, however.

Keep reading

Delaware Bill Aims To Relax Buffer Zones Between Marijuana Businesses

A new state bill is being proposed that would give marijuana operators more options to place their shops throughout Delaware but may also inflame opponents who have sought restrictions.

The bill comes as local municipalities and counties continue to debate where marijuana shops should be allowed, following the legalization of the recreational marijuana market in 2023, which is set to launch soon.

The restrictions have led to about a third of Delaware’s municipalities deciding to ban marijuana shops outright from their town limits.

Under the current state law, municipalities are allowed to ban marijuana businesses, but counties are only allowed to set restrictions on where they can operate.

The new bill, Senate Bill 75, sponsored by State Sen. Trey Paradee (D-Dover) and filed late last week, will force the state’s three counties to decrease the buffers they created between marijuana shops and sensitive areas like schools, treatment facilities and libraries down to no more than 500 feet.

Paradee said the bill is aimed at addressing concerns that marijuana shop licensees are facing in Sussex County, as more than half of its towns have opted out of having marijuana shops in their jurisdictions and the county has set the widest buffers between shops and sensitive areas at 3,000 feet.

“They effectively made marijuana illegal in Sussex County, and that’s not what the voters of the state want, and that is not what the General Assembly voted for,” Paradee said.

He said the bill will also address the frustrations of business license holders in New Castle County, where some licensees told Paradee they also cannot find eligible space to operate. The northernmost county currently has a buffer set at 1,000 feet.

Keep reading

Indiana Lawmakers Approve Bill To Ban Marijuana Advertising On Billboards

Tuesday discussion around a Bureau of Motor Vehicle (BMV) bill descended into impassioned debate over marijuana advertising, which Republican lawmakers said should be restricted.

In contention was House Bill 1390, authored by Rep. Jim Pressel (R-Rolling Prairie). The underlying legislation originally just dealt with BMV agency matters, like insurance verification, specialty license plates and registration stickers.

But among multiple changes adopted by the Senate Homeland Security and Transportation Committee on Tuesday—including a significant amendment addressing “predatory” towing—was a ban on “outdoor” marijuana advertising, notably on highway billboards.

Specifically, the amended bill language seeks to prohibit outdoor advertisements for products containing marijuana or a variety of other controlled substances, including heroin, LSD and ecstasy.

The bill now moves to the Senate Appropriations Committee.

Pressel, whose district extends to Indiana’s northern border, described “billboards all over the place that say, ‘Come to my store and buy this,’” referencing dispensaries in Michigan, where recreational marijuana is legal.

“And we have trucks—mobile billboards—that drive around and sit in front of our parks. That’s unacceptable, and it sends a mixed message to the consumer that this product is legal in Indiana, which it is not,” said Pressel, who unsuccessfully attempted to add the provision to a separate House bill earlier in the session.

“I think that’s an unfair message,” he continued, “and I believe that we should get in front of this to say that if it’s an illegal substance, listed on our illegal substance list in the state of Indiana, you should not be able to advertise for that.”

Multiple advertisers pushed back.

Ron Breymier, executive director of the Outdoor Advertising Association of Indiana, cited First Amendment issues. He argued that policymakers can dictate the size and placement of billboards, but “not the actual advertisement itself.”

Phones and internet searches, Breymier said, are a “greater threat” than billboards.

Keep reading

CBD-Rich Cannabis Offers ‘Potential Benefits’ For People With Autism Spectrum Disorder, Scientific Review Finds

A new review of scientific research on the use of marijuana’s components to treat autism spectrum disorder (ASD) finds that “preliminary evidence suggests potential benefits,” including improvements around anxiety, sleep and behavior. But more work—especially randomized controlled trials—are needed “to confirm these results and establish clear treatment guidelines,” authors said.

“Preliminary findings suggest that CBD-rich formulations may provide modest benefits for sleep and social interaction, with a reduction in anxiety symptoms,” says the peer-reviewed study, published in the journal Cureus. “Regarding core ASD symptoms and behavioral outcomes, cannabinoids demonstrated greater efficacy compared to placebo in some studies.”

Researchers also acknowledged that “adverse events varied” among patients, and “response to treatment was inconsistent across individuals,” underscoring the need for further study.

“While cannabinoids, particularly CBD-rich formulations, appear to be relatively safe and potentially beneficial,” the new paper says, “further large-scale, controlled trials comparing CBD to established ASD treatments are essential to clarify its role and long-term impact in ASD management.”

The 13-person team behind the new study includes researchers from various hospitals and universities in Brazil.

Overall, they wrote, “While preliminary evidence suggests potential benefits, particularly for anxiety, sleep, and behavior, the findings remain inconclusive due to study heterogeneity and methodological limitations.”

For the analysis, authors looked at seven studies involving 494 patients, focusing on “key clinical outcomes, such as sleep, autistic core symptoms, anxiety, behavior, social effects, and adverse events.”

“Improvements were noted in anxiety, sleep quality, social effects, and behavior, although these findings varied across studies,” they concluded. “Importantly, adverse events were generally mild and occurred at similar rates in cannabinoid and placebo groups, supporting the intervention’s safety profile.”

Studies also indicated “a slight improvement” in sleep quality, while “autistic core symptoms showed positive responses” the report says. “Some studies also reported reductions in hyperactivity, agitation, self-injurious behavior, and epilepsy, along with improvements in communication skills, attention, and eye contact.”

Drowsiness was the most common side effect, followed by decreased appetite, weight loss, anxiety and restlessness.

Keep reading

Federal Official Downplays Criticism That Saliva-Based Marijuana Testing As Urine Alternative Would Spur Use By Truckers

Amid ongoing discussions about how to ensure drivers aren’t impaired by marijuana, a federal official recently pushed back on criticism that proposed implementation of saliva-based drug testing could incentivize more cannabis use by commercial truckers.

In comments to the publication Transit Topics, an unidentified official from the Substance Abuse and Mental Health Services Administration (SAMHSA) responded to assertions from the CEO of a drug-testing company that oral fluid testing “means truckers who use cannabis will be able to do so with near impunity, as long as they avoid a drug test for a couple of days.”

The contention of the CEO—Ken Fichtler, of Gaize—was that the Department of Transportation’s (DOT) “shift to oral fluid testing will have serious consequences for the trucking industry” because saliva testing has a shorter detection window than typical urine-based testing. He said the tests detect use within the past “24 to 48 hours,” which is far shorter than the period of weeks when marijuana metabolites can be detected in urine.

DOT finalized the new testing policies in 2023 to allow oral saliva drug testing as an alternative to urine-based tests.

The SAMHSA official, granted anonymity by Transit Topics, disputed Fichtler’s claims—both on the test’s detection window itself and the implications of DOT’s revised testing policies for truckers’ marijuana use.

“In referenced journal articles, cannabis use can be detected via oral fluid testing for up to 72 hours,” the official said. “When a donor receives a request for collection, the donor will not know if the test will be an oral fluid or urine collection until they arrive at the collection facility for a federal agency.”

Not knowing whether to expect a saliva or urine test, in other words, would prevent the situation described by Fichtler of drivers simply stopping marijuana use a few days before a saliva-based test.

Keep reading

Nebraska Bill To Implement Voter-Passed Medical Marijuana Law Awaits Changes Ahead Of Committee Vote

The legislative committee mulling how to help implement Nebraska’s voter-led medical cannabis laws awaits an amendment before lawmakers vote on whether to advance the bill.

Legislative Bill 677, from state Sen. Ben Hansen (R-Blair), seeks to help carry out the overwhelming voter approval to legalize and regulate medical cannabis in the state last fall. His bill would create a regulatory structure for licensing and detail how patients or caregivers could become registered to obtain up to five ounces of physician-recommended cannabis at one time.

State Sen. Rick Holdcroft (R-Bellevue), chair of the Legislature’s General Affairs Committee, said last week that he and seven other committee members were awaiting a final amendment that could help the currently deadlocked committee decide whether to advance the bill.

“The people have spoken, and we need to put in place the best possible regulatory structure,” Holdcroft told the Nebraska Examiner.

Hansen has said one key change in his amendment would be tracking medical cannabis through the state’s prescription drug monitoring program, similar to the process for opioids. At least nine states use a local prescription drug monitoring program to carry out local medicinal cannabis laws.

The Blair senator has also voiced support for defining a “qualifying medical condition” for which a health care practitioner may recommend the drug and requiring that a physician be required to be appointed to one of the two at-large spots on the Nebraska Medical Cannabis Commission charged with regulating and implementing the laws.

The new commission automatically includes the three commissioners of the Nebraska Liquor Control Commission. Under current law, the governor has the option to appoint two more members.

‘The people have spoken’

Keep reading

Minnesota Lawmakers File Bill To Legalize Psilocybin Possession And Cultivation

Minnesota lawmakers have introduced a bill that would legalize the non-commercial possession and cultivation of psilocybin by adults 21 and older.

Rep. Andy Smith (D) filed the legislation on Monday, with seven original cosponsors. The measure largely informed by the findings and recommendations of a task force that was established under a separate bill that Gov. Tim Walz (D) signed into law in 2024.

“I’ve had a couple folks ask me this: ‘We’re in a tight moment. Inflation is rising. Why is this something that you’re working on?’” Smith, who served on the task force and whose prior legislation created the body, told Marijuana Moment in a phone interview on Tuesday. “And it goes back to, all of us recognize, know someone or struggle ourselves with mental health—and that has been apparent for a while.”

“I think the pandemic highlighted how much we have to go as a society and how we deal with very complex issues, and these medications have shown, in studies, to have great potential to help in that,” Smith said. “I think that’s why it’s important—and it’s important to move on these quickly and responsibly.”

Under the lawmaker’s proposal, the state law would be revised to make it so adults would not face criminal or civil penalties for the personal “use, possession, transportation and cultivation.”

The purpose section of the legislation states that the reform is meant to “reduce the burden on the criminal justice system, promote harm reduction, and enable individuals to make personal decisions regarding the use of psilocybin without fear of prosecution.”

A Psychedelic Medicine Board would be established under the bill to establish possession limits. Smith said that requirement—as well as components that may prove more controversial in an especially divided legislature such as decriminalizing cultivation—will likely be up for debate as the measure moves through the process.

Keep reading